Wayne Anliker, MD
Ophthalmology · Emporia, KSNPI 1477557247
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 71.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $215 and has fallen 59.4% since, to $87 in 2025. That places this record below the midpoint for ophthalmology clinicians in KS, where the typical reported total is $1,383.
Across 32 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$449
- Amgen$44
- Carl Zeiss Meditec USA, Inc.$27
- Carl Zeiss Meditec, Inc.$25
- Aerie Pharmaceuticals, Inc.$22
- Sight Sciences, Inc.$20
- plus $42 from 3 others
What the payments were for
- Food & beverage$629100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 22 | $449 |
| Amgen(2 entities) | 2 | $44 |
| Carl Zeiss Meditec USA, Inc. | 2 | $27 |
| Carl Zeiss Meditec, Inc. | 1 | $25 |
| Aerie Pharmaceuticals, Inc. | 1 | $22 |
| Sight Sciences, Inc. | 1 | $20 |
| Biotissue Holdings Inc. | 1 | $16 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
| AbbVie | 1 | $13 |
How this compares
$629 in reported general payments places this provider in the 30th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 1,231 | $36,957 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 942 | $6,629 |
| Ketorolac Tromethamine | 178 | $3,020 |
| Brimonidine Tartrate | 28 | $1,890 |
| Latanoprost | 246 | $1,589 |
| Travoprost | 11 | $1,563 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $693 |
| Dorzolamide Hcl | 30 | $316 |
| Timolol Maleate | 54 | $274 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Emporia
- Daniel DurrieOverland Park$974K
- John DoaneLeawood$496K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Blake CooperLenexa$100K
- Miranda BisharaPrairie Village$45K
- Jeff WongskhaluangOlathe$42K
- Michael EllisLenexa$38K
- Matthew SniegowskiLeawood$22K
- Michele RigginsWichita$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.